OR WAIT null SECS
© 2021 MJH Life Sciences and Ophthalmology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Washington, DC-The Centers for Medicare and Medicaid Services (CMS) once again plans to expand its coverage for ocular photodynamic therapy (OPT) with verteporfin (Visudyne, Novartis Ophthalmics).